Advisory · Infectious Disease
Post-pandemic restructuring has created a valuation reset.
Ambrosia provides senior-led advisory for infectious disease licensing, M&A, and strategic partnerships — backed by a proprietary database of 100 verified infectious disease transactions.
Deal Landscape
What infectious disease transactions actually look like.
Verified Transactions
100
Median Upfront
$45M
Key Structure Insight
Antiviral and vaccine economics diverged sharply post-2023
Related Insights
Research relevant to infectious disease.
Discuss your infectious disease transaction.
We’ll meet you at peer level — anywhere in the world.